Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s traded shares stood at 1.08 million during the last session, with the company’s beta value hitting 0.91. At the close of trading, the stock’s price was $4.15, to imply an increase of 5.33% or $0.21 in intraday trading. The CRVS share’s 52-week high remains $10.00, putting it -140.96% down since that peak but still an impressive 68.67% since price per share fell to its 52-week low of $1.30.
Analysts have given a consensus recommendation of Buy for Corvus Pharmaceuticals Inc (CRVS), translating to a mean rating of 1.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give CRVS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.12.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS) trade information
After registering a 5.33% upside in the last session, Corvus Pharmaceuticals Inc (CRVS) has traded red over the past five days. The 5-day price performance for the stock is -8.08%, and -18.15% over 30 days. With these gigs, the year-to-date price performance is -22.43%.
The extremes give us $12 and $13 for target low and target high price respectively. As such, CRVS has been trading -213.25% off suggested target high and -189.16% from its likely low.
Corvus Pharmaceuticals Inc (CRVS) estimates and forecasts
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 19.89% for the past 5-year period. While 2025 is set for a -64.58% return in earnings, projections for the next 5 years are at -2.42% annually.
CRVS Dividends
Corvus Pharmaceuticals Inc has its next earnings report out in March. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Corvus Pharmaceuticals Inc (NASDAQ:CRVS)’s Major holders
The next major institution holding the largest number of shares is SAMLYN CAPITAL, LLC with 6.12 million shares, or about 10.2546% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $11.14 million.
We also have Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund as the top two Mutual Funds with the largest holdings of the Corvus Pharmaceuticals Inc (CRVS) shares. Going by data provided on Sep 30, 2024, Vanguard Total Stock Market Index Fund holds roughly 1.58 shares. This is just over 2.46% of the total shares, with a market valuation of $6.56 million. Data from the same date shows that the other fund manager holds a little less at 767.02, or 1.19% of the shares, all valued at about 3.18 million.
